Kornimate/medical-research-clean huggingface dataset:
positron nuclide labeled nota-fapi pet study in lymphoma

Conditions: Tumor, Solid; Positron-Emission Tomography; Lymphoma

Summary: to evaluate the normal physiological distribution of positron nuclide labeled nota-f api in human body and its detection efficiency for lymphoma

subjects first undergo an 18f-fdg test, followed by 68ga-nota-fapi04 or 18f-nota-fapi04 test in groups.investigate the standardized uptake value(suv) of 68ga/ 18f-nota-fapi04 for the target lesion, the ratio of the standardized uptake value(suvr) of 68ga/ 18f-nota-fapi04 for the target lesion within each time window to that of the normal corresponding tissue.

Eligibility criteria:
inclusion criteria: * ecog score 0 or 1 * subjects with lymphoma or suspected tumor subjects who have recently (within 2 months) planned to receive pathological biopsy or tumor surgery * expected survival ≥12 weeks * blood routine, liver and kidney function meet the following criteria: blood routine: wbc≥4.0×109l or neutrophils ≥1.5×109l, plt≥100×109/l, hb≥90g/l;pt and aptt uln 1.5 or less;liver and kidney function: t-bil ≤1.5×ult(upper limit of normal value), alt/ast≤2.5uln or ≤5×ult(subjects with liver metastasis), alp≤2.5uln(alp≤ 4.5uln if there is bone metastasis or liver metastasis);bun 1.5 x or less ult, scr 1.5 x or less ult * at least one measurable target lesion according to recist1.1 * women must use effective contraception during the study period and for 6 months after the end of the study (effective contraception means sterilization, hormone devices, condoms, contraceptives/pills, abstinence or vasectomy by a partner, etc.);men should consent to subjects who must use contraception during the study period and for 6 months after the end of the study period * able to understand and sign the informed consent voluntarily, with good compliance. exclusion criteria: * severe abnormalities of liver and kidney function; * women preparing for pregnancy, pregnancy and lactation; * cannot lie supine for half an hour; * refuse to join the clinical researcher; * suffering from claustrophobia or other mental illness; * conditions that other researchers considered inappropriate for the study.

Keywords: lymphoma positron-emission tomography fapi
study of brain function evaluation and intervention system for acute and prolonged disorders of consciousness

Conditions: Disorder of Consciousness

Summary: the research focuses on establishing a system for validating the effectiveness of key technologies for targeted combined non-invasive interventions in awakening consciousness.

analyzed the eeg activity and brain network changes before and after stimulation by tms stimulation of key brain regions, and correlated them with brain function. to verify the "time-frequency-space" neural mechanism of consciousness.

Eligibility criteria:
admission criteria for patients with prolonged disorders of consciousness (total 200) inclusion criteria:(1)age 14-80 years;(2)in accordance with the diagnostic criteria of unresponsive arousal syndrome or minimally conscious state by international research;(3)brain trauma, stroke and hypoxic-ischemic encephalopathy lead to disturbance of consciousness;(4) right-handed；(5)the patient's family members signed the informed consent form; exclusion criteria:(1)the history of mental illness and a history of hearing impairment;(2)intracranial arterial clamp, pacemaker and other metal implants; (3)during the experiment, sedatives and other drugs that affect the excitability of the cortex;(4)the presence of uncontrolled seizures or involuntary movements; admission criteria for patients with acute disorders of consciousness(total 300) inclusion criteria:（1)age 14-60 years;（2）meets diagnostic criteria for coma recognized in international studies；(3)the gcs score was less than 8; (4)brain trauma, stroke and hypoxic-ischemic encephalopathy lead to disturbance of consciousness;(5) right-handed；(6)the patient's family members signed the informed consent form; exclusion criteria:(1)the history of mental illness and a history of hearing impairment;(2)intracranial arterial clamp, pacemaker and other metal implants; (3)during the experiment, sedatives and other drugs that affect the excitability of the cortex;(4)the presence of uncontrolled seizures or involuntary movements; admission criteria for patients with acute disorders of consciousness;(5)no spontaneous breathing;(6)status epilepticus;(7)need emergency neurosurgical treatment can not cooperate with the examination;

Keywords: tms non-invasive neuromodulation brain function test
post operative pain control for distal radius surgery: does exparel injected at the surgery site improve postoperative pain scores at 24 and 48 hours ?

Conditions: Post Operative Pain

Summary: the purpose of this study is to see if exparel, used intraoperatively by injecting at the surgical site, followed by a supraclavicular nerve block with bupivacaine in the recovery room, will provide better pain scores for patients at 24 and 48 hours post operatively than, 1)bupivacaine hydrochloride (hcl) injection at the surgical site, with a supraclavicular block in post-anesthesia care unit(pacu), or 2)a supraclavicular block in pacu without any kind of injection at the surgical site.


Eligibility criteria:
inclusion criteria: * distal radius fractures * undergoing open reduction internal fixation (orif) at lyndon b johnson ambulatory surgical center (lbj asc) exclusion criteria: * pregnancy * history of chronic pain conditions * currently taking opioids

Keywords: brachial plexus block multimodal pain control for distal radius surgery exparel bupivacaine distal radius pain control post operative pain control supraclavicular nerve block
lymphatic mapping after previous breast surgery

Conditions: Breast Cancer; Sentinel Node

Summary: rationale: like in primary breast cancer, prognosis in recurrent breast cancer is correlated with regional lymph node status. therefore, axillary staging may be warranted in patients with recurrent disease and intact axillary nodes, although this has not been described in guidelines yet. the lymphatic drainage pathways in the breast and/or axilla could have been changed due to prior surgery and/or radiotherapy. these aberrant drainage pathways could be detected with lymphatic mapping and sentinel node biopsy (snb), leading to a more accurate staging. objective: to assess the technical feasibility of lymphoscintigraphy after prior breast surgery. a second goal is to investigate whether or not previous breast surgery (with or without radiotherapy) significantly changes the lymphatic drainage pathways of the breast.


Eligibility criteria:
inclusion criteria: * treatment with bct with snb and/or alnd for primary breast cancer * previous primary breast cancer located in the upper-outer quadrant of one breast * primary breast cancer treatment at least 3 years before the analysis, with or without adjuvant chemo- or hormonal therapy. exclusion criteria: * breast surgery for other reasons than breast cancer * recurrent breast cancer * former allergic reaction to 99mtc-colloidal albumin.
efficacy and tolerability study of two dosing regimens of ctp-543 in adults with alopecia areata

Conditions: Alopecia Areata

Summary: this study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of ctp-543, in adult patients with chronic, moderate to severe alopecia areata.


Eligibility criteria:
inclusion criteria: * clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of screening. total disease duration greater than 10 years is permitted. * at least 50% scalp hair loss, as defined by a severity of alopecia tool (salt) score ≥50, at screening and baseline. exclusion criteria: * active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis on the scalp. * treatment with systemic immunosuppressive medications within 3 months of screening or during the study, or biologics within 6 months of screening or during the study. * clinical lab results outside the normal range.
the spatiotemporal gait parameters in ldh patient

Conditions: Lumbar Disc Herniation; Pain

Summary: the aim of this study was to assessment on the interaction of spatial and temporal gait parameters and gait asymmetry in patients with lumbar disc herniation (ldh) before and 15 days after surgery.

the participants were divided into ldh and healthy control groups. the analysis of the spatiotemporal gait parameters was performed using the "win-track" gait analysis platform system for two groups. in addition, the analysis of spatiotemporal gait parameters of 60 participants who had the planned lumbar discectomy surgery, was tested before and 15 days after surgery. the pain intensity of the patients was recorded by the visual analog scale (vas) immediately before performing the analysis. after then participants completed ten passes on the "win-track" gait analysis platform at their self-selected walking speed. the arithmetic mean of the three flawless walking data was used for analysis. the gait symmetry index was used to calculate the walking asymmetry.

Eligibility criteria:
inclusion criteria: * individuals who were diagnosed with ldh by a specialist; * patients had a medical history and proven by mri with more or less evidence of degenerative lumbar disc; * aged between 25-80 years old; * pain symptom on the lumbal area or lower extremity. exclusion criteria: * patients who have previously received surgery or physical therapy treatment; * having congenital deformity in the spine or lower extremity; * history of spinal surgery or other diseases affecting gait; * pregnancy; * situations that may cause gait balance problems; * using assistive gait appliance.

Keywords: pain gait analysis lumbar disc herniation spatiotemporal gait parameters gait asymmetry
kidney fibrosis and mri

Conditions: Kidney Diseases

Summary: the investigators plan a prospective cross-sectional study of pediatric and adult healthy volunteers and patients with chronic kidney disease that will correlate a variety of quantitative mri biomarkers with severity of renal insufficiency and available histopathology. over 3 years, the investigators will recruit approximately 20 healthy volunteers, 20 patients with chronic kidney disease (ckd) stage 2-5, and 20 patients with renal transplant kidneys. the investigators also plan to assess the effect of inflammation on the quantitative mri biomarkers by recruiting approximately 20 additional patients with active lupus nephritis.


Eligibility criteria:
inclusion criteria: subjects who meet all of the following criteria will be eligible for the study: 1. ≥ 10 and ≤ 25 years of age and; 2. kidney transplant patients, who have had a recent kidney biopsy (within 1 year) that shows interstitial fibrosis or 3. patients with ckd stage 2-5 who have previously had a biopsy (within 1 year) or 4. lupus patients with active nephritis who will undergo biopsy evaluation before and after induction therapy or 5. healthy controls exclusion criteria: subjects who meet any of the following criteria will be excluded from the study: 1. known contraindication to mr imaging (e.g., implanted non-mri compatible device) 2. known or suspected pregnancy. female subjects of child bearing potential will undergo a urine pregnancy test prior to imaging. 3. inability to undergo mri without sedation/anesthesia. 4. non-english speaking
evaluation of a novel methodology in the assessment of urethral function using [s,s]-reboxetine in healthy volunteers

Conditions: Healthy

Summary: \[s,s\]-reboxetine will be used to evaluate pharmacodynamic changes in urethral function in healthy volunteers using a novel methodology


Eligibility criteria:
inclusion criteria: * healthy female subjects, aged 18-65 years. * subjects must be non-pregnant and non-lactating, and be either post menopausal (greater than 1 year without menses), surgically sterilized, or using another acceptable form of contraception. * subjects of child bearing potential must have confirmed negative pregnancy tests at screening and prior to commencing all study periods. exclusion criteria: * evidence or history of clinically significant disease (including drug allergies, but excluding untreated, asymptomatic,seasonal allergies at time of dosing). * subjects with any clinically significant abnormality following review of laboratory data, urinalysis and physical examination.

Keywords: equipment supplies
hematologic ratios in postoperative acute kidney injury

Conditions: Acute Kidney Injury

Summary: acute kidney injury (aki) is a common complication after surgery for congenital heart disease and is associated with significant morbidity and mortality. to-date, no biomarker has been universally implemented for predicting aki in neonates after cardiac surgery. in this study, the use of hematological ratios will be evaluated for predicting aki and postoperative outcomes in this patient cohort.

in adults, hematological ratios which can be calculated from a routinely ordered complete blood count with differential, such as the neutrophil/lymphocyte ratio, have been demonstrated to be correlated with acute kidney injury (aki) and other clinical outcomes after cardiovascular surgery. in this retrospective observational study, the association between hematological ratios (neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, neutrophil/lymphocyte\*platelet ratio, monocyte/lymphocyte ratio, and plateletcrit) and postoperative aki, morbidity (length of icu stay, hospital stay, mechanical ventilation, vasoactive infusion-free days, etc.) and mortality will be evaluated in neonates who underwent cardiac surgery with cardiopulmonary bypass.

Eligibility criteria:
inclusion criteria: * neonates (≤31 days) who underwent cardiac surgery with cardiopulmonary bypass for congenital heart disease. exclusion criteria: * patients with missing relevant preoperative or postoperative data points * patients with previous palliation or reoperation, * thymus hypo/aplasia (digeorge syndrome, ataxia-telangiectasia, or nezelof syndrome), * primary immunodeficiency, * episode of cardiac arrest within 1 week before surgery, * signs or history of preoperative renal impairment or aki (kdigo stage ≥1 observed on preoperative labs), * hypothyroidism, * patients with a history of infection within a week prior to surgery or antibiotics administered within the first 3 days after surgery (except for postoperative antibiotics).

Keywords: acute kidney injury cardiac surgery cardiopulmonary bypass congenital heart disease biomarkers
evaluation of desensitization protocols in hla-incompatible kidney-transplant candidates

Conditions: End-stage Renal Disease; Kidney Transplantation; Hla-incompatible Kidney Transplant Candidates

Summary: kidney transplantation is the best renal-replacement in the setting of end-stage renal disease. however, some transplant candidates have developed anti-hla alloantibodies (human leukocyte antigen). when they are numerous and when their strength assessed by mean fluorescence intensity (mfi) is high it is very complicated to find-out a suitable kidney allograft against which the recipient has a negative cross-match. in such a case the only hope for the patient is desensitization therapy, whereby the treatment will decrease anti-hla alloantibodies below a threshold, i.e. mfi \< 3,000, enabling kidney transplantation without risking antibody-mediated rejection. desensitization relies on i) apheresis technics in order to withdraw circulating anti-hla antibodies, and ii) immunosuppression, i.e. rituximab or tocilizumab, targeting b-lymphocytes, and tacrolimus/mycophenolic acid/steroids targeting t-cells. the type of apheresis is guided by the pre-desensitization mfi of anti-hla alloantibodies, e.g. double filtration plasmapheresis or semispecific immunoadsorption. likely the choice between rituximab and tocilizumab depends also on predesensitization anti-hla antibody mfis. at the end of the desensitization process, the patient will be able to get a kidney transplant either from a live-donor or from a deceased donor.


Eligibility criteria:
inclusion criteria: * patients on the kidney transplant list, waiting for a first or repeat transplant * presence of anti hla antibodies either class i and/or ii * sensitized against a potential living donor or have been on the waiting list for at least 3 years and having no potential live-donor * patients eligible for desensitization will receive either rituximab alone, or rituximab plus apheresis, or tocilizumab before rituximab * normal recent (\<6 months) cardiac workup * vaccinated against pneumococcus and meningococcus b and c * willingness of the patient to undergo the desensitization process and express consent of the patient * for women of childbearing age, effective contraception or abstinence * affiliated to a social security scheme or of such a scheme exclusion criteria: * active underlying infections or neoplasia * pregnant women, parturient or breastfeeding * subject in exclusion period of another study * subject under administrative or judicial control * subject who cannot be contacted in an emergency * rituximab contra indication: hypersensitivity (to active substance or murine protein), active and severe infections, patients in a severely immunocompromised state, severe heart failure or severe, uncontrolled cardiac disease. * tocilizumab contra indication: hypersensitivity, active and severe infections. apheresis contra indication: active and severe infection, untreated or instable coagulation disorders, unstable coronary disease, recent stroke, hemodynamic instability.

Keywords: anti-hla alloantibodies desensitization therapy tocilizumab rituximab
efficacy of nasojejunal enteral feeding in critically ill patients.

Conditions: Critically Ill

Summary: the purpose of this study is to determine if naso-jejunal feeding (feeding beyond the stomach) improves the efficacy of enteral feeding (feeding into the gut) in critically ill patients. the study hypothesis is that in patients who fail to establish enteral feeding via the nasogastric route, introduction of nasojejunal feeding will lead to more effective enteral feeding than the current regime involving staged introduction of promotility agents.

the study examines the area of enteral feeding in critically ill patients. current standard enteral feeding practice is via a nasogastric with the addition of promotility agents for patients who fail to absorb their enteral nutrition. this study compares the efficacy of nasojejunal feeding feeding with nasogastric enteral feeding with the addition of promotility agents. the duration of feeding will be determined by the patients nutritional requirements and their general condition. however the data will be collected for duration of enteral feeding, 28 days or icu discharge whichever occurs first.

Eligibility criteria:
inclusion criteria: 1. adult patients (18years or over) admitted to the icu with an expected stay of more than 48 hours. 2. patients commenced on enteral feeding via a nasogastric tube who fail to tolerate gastric feeding due to excessive gastric aspirate volumes. 3. patients who consent or if the patient is incompetent, the next of kin, who consent, to inclusion in the study. - exclusion criteria: 1. patients less than 18 years of age. 2. patients with known allergy to promotility agents, metoclopramide or erythromycin. 3. patients with a contra indication to nasojejunal feeding. -
wellness action plan trial addressing childhood obesity

Conditions: Childhood Obesity

Summary: the objective of this study was to determine the effectiveness of a novel wellness action plan aimed at 1) improving parent recall of diet and activity plans 2) increasing follow-through with plans and 3) aiding parents in identifying their child's weight category.


Eligibility criteria:
inclusion criteria: * children between the ages of 2.5 and 14 years, regardless of baseline bmi * presented for a well child visit at a pediatric clinic serving primarily medicaid-insured children in milwaukee, wisconsin exclusion criteria: * patients in foster care * parents and patients who were non-english speaking * patients who were being seen by a specialist for weight management.

Keywords: pediatric obesity body mass index weight perception counseling health behavior
observation of the efficacy of different vitrectomy systems to treat proliferative diabetic retinopathy

Conditions: Proliferative Diabetic Retinopathy; Vitrectomy

Summary: in recent years, vitrectomy has moved toward a minimally invasive vitrectomy surgery (miv) system, which could effectively reduce the occurrence of operation complications, while reducing the time of post-operation recovery. with an improved design of bevel tip and a high cutting rate capacity of 10000cpm, advanced ultravit® probes potentially provide an strong technical support for the application of miv. the new probe facilitates great control during delicate surgical maneuvers, such as separating the hyaloid from the retinal surface, dissecting fibrovascular tissue off the surface of retina. however, there was no sufficient clinical evidence to support the benefits of advanced ultravit ® probes in the complicated vitreoretinal surgery, such as proliferative diabetic retinopathy. more importantly, there is an urgent need of clinical evidence to support 10000cpm launch and conversion which is major objective of 2021 vr growth strategies.

this exploratory study, aiming to demonstrate the beneficial of 27 gauge probe, which can be flexibly applied as a multifunctional tool for membrane removal by reducing frequencies of switching device, reducing the traction to eyeball during device entering and leaving the eye. moreover, the outcomes from this study would be an strong evidence to support further comparative study to comprehensively demonstrate the superior function compare to current heavily used 5k 25 gauge probe.

Eligibility criteria:
inclusion criteria: 1. patients with vitreous hemorrhage and tractional retinal detachment (trd) confirmed by fundus image and b ultrasound examination, consistent with the diagnosis of severe proliferated diabetic retinopathy (pdr). 2. patient that could follow up postoperatively at the clinic for 6 months more. 3. all the surgeries were performed by one well-experienced retinal surgeon. exclusion criteria: 1. corneal lesions affecting operative field, such as corneal opacity or scar; history of vitreoretinal surgery; 2. external eye infections; 3. history of systemic thromboembolism; 4. uncontrolled hypertension or hyperglycemia; 5. coagulation abnormalities or currently using anticoagulant drugs other than aspirin; 6. unable to meet postoperative position requirements; 7. unable to be followed up regularly.
study to assess the efficacy and safety of ublituximab in participants with relapsing forms of multiple sclerosis (rms)

Conditions: Relapsing Multiple Sclerosis (RMS)

Summary: this study determines the annualized relapse rate (arr) in participants with rms after 96 weeks (approximately 2 years) treatment with intravenous (iv) infusion of ublituximab/oral placebo compared to 14 mg oral teriflunomide/iv placebo.


Eligibility criteria:
inclusion criteria: * diagnosis of relapsing multiple sclerosis (rms) (mcdonald criteria 2010) * active disease * expanded disability status scale (edss) 0 - 5.5 (inclusive) at screening exclusion criteria: * treatment with prior anti-cluster of differentiate 20 (cd20) or other b cell directed treatment * treatment with the following therapies at any time prior to randomization: alemtuzumab, natalizumab, teriflunomide, leflunomide and stem cell transplantation * diagnosed with primary progressive multiple sclerosis (ppms) * pregnant or nursing